Welcome to our dedicated page for Alpine Immune Sciences news (Ticker: ALPN), a resource for investors and traders seeking the latest updates and insights on Alpine Immune Sciences stock.
Founded in 2015, Alpine Immune Sciences, Inc. (NASDAQ: ALPN) is a leading clinical-stage biotechnology company dedicated to developing innovative protein-based immunotherapies to treat autoimmune and inflammatory diseases. Alpine leverages its unique understanding of immunology, particularly recombinant protein-based immunotherapies, to modify the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases.
Alpine's standout product, povetacicept (ALPN-303), is a dual antagonist of the BAFF and APRIL cytokines. This product is currently in phase 2 development and has demonstrated potential best-in-class efficacy for treating IgA nephropathy (IgAN). IgAN is a serious, progressive kidney disease with no approved therapies that target its underlying cause. Povetacicept has exhibited promising results in reducing proteinuria, stabilizing renal function, and reducing key disease-related biomarkers.
Additionally, Alpine has a robust pipeline, including acazicolcept (ALPN-101), a first-in-class dual inhibitor targeting the CD28 and ICOS T-cell costimulatory pathways. This drug is being investigated for treating systemic lupus erythematosus (SLE) and other autoimmune diseases. Alpine's research and development capabilities are enhanced by strategic collaborations with leading global biopharmaceutical companies, propelling its efforts to create multifunctional immunotherapies that improve patients' lives.
The company has been highly productive in the past year, achieving significant milestones, such as the phase 2 study of acazicolcept in SLE, a pivotal phase 3 trial of povetacicept in IgAN planned for the second half of 2024, and successful financial activities supporting ongoing and future development projects.
Alpine Immune Sciences remains committed to innovation, with ongoing studies in various autoimmune diseases and strategic goals aligning with its mission to lead a new wave of immune therapeutics.
Alpine Immune Sciences (NASDAQ: ALPN) reported Q3 2022 financial results, highlighting a cash position of $277.1 million, sufficient to support operations through 2025. The company successfully raised $113 million to accelerate the development of ALPN-303, showing promising results in clinical trials for autoimmune diseases, including IgA nephropathy. A phase 2 study in systemic lupus erythematosus is planned, along with basket studies in related conditions. However, collaboration revenue slightly declined to $8.4 million, and the company reported a net loss of $13.3 million.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced it will release its third quarter 2022 financial results on November 14, 2022, after market close. A conference call and live webcast will take place at 4:30 p.m. ET. The webcast will be accessible via their investor relations website, with a replay available for 90 days post-event. Alpine is focused on developing innovative immunotherapy treatments for autoimmune and inflammatory diseases, backed by strong research collaboration and a diverse pipeline of candidates.
Alpine Immune Sciences presented new data on ALPN-303 at the American Society of Nephrology Kidney Week 2022, showcasing its potential in treating IgA nephropathy (IgAN). The phase 1 study (RUBY-1) demonstrated that ALPN-303 is well tolerated in doses up to 960 mg and shows dose-dependent effects, reducing serum galactose-deficient IgA1 (Gd-IgA1) by up to 60%. These findings support plans for future clinical trials focusing on glomerulonephritis. The company emphasizes ALPN-303's best-in-class profile and its promising role in various autoimmune conditions.
Alpine Immune Sciences (NASDAQ: ALPN) announced a poster presentation at the American Society of Hematology meeting happening from December 10-13, 2022. The presentation will discuss the phase 1 study (RUBY-1) of ALPN-303, a dual BAFF/APRIL antagonist for treating autoimmune cytopenias. The study aims to assess the drug's safety, tolerability, and pharmacokinetics in healthy volunteers, with initial data supporting a dosing regimen of once every four weeks. The poster will be displayed on December 12, 2022, at 6:00 PM EST.
Alpine Immune Sciences (NASDAQ: ALPN) announces poster presentations for the phase 1 study of ALPN-303 at prestigious conferences. The American Society of Nephrology's Kidney Week 2022 and the American College of Rheumatology Convergence 2022 will showcase findings on the safety and pharmacokinetics of ALPN-303, a dual BAFF/APRIL antagonist targeting autoimmune diseases. Initial results show it is well tolerated with dose-dependent effects, supporting a once-every-four-week dosage regimen for future investigations.
Alpine Immune Sciences (NASDAQ: ALPN) has announced the voluntary termination of enrollment in its clinical studies for davoceticept (ALPN-202) due to patient safety concerns following two deaths in the NEON studies attributed to cardiogenic shock. The decision prioritizes the safety of participants and allows the company to redirect focus towards advancing ALPN-303, a promising dual BAFF/APRIL B cell cytokine inhibitor for autoimmune diseases, and acazicolcept (ALPN-101) for systemic lupus erythematosus. The company plans to conduct a phase 2 study for ALPN-303 and further evaluations in various autoimmune conditions.
Alpine Immune Sciences announced a public offering of 13,606,000 shares of common stock at $7.35 per share. Expected gross proceeds are approximately $100 million. The offering is conducted under an existing shelf registration statement. An additional 2,040,900 shares may be purchased by underwriters within 30 days. The offering aims to close on or about September 23, 2022. Morgan Stanley, SVB Securities, and Cowen are managing the offering. This press release includes forward-looking statements regarding market conditions and the offering's anticipated closure.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) has launched a public offering of $100 million in common stock, which includes pre-funded warrants for select investors. The underwriters may purchase an additional $15 million of shares within 30 days. The offering is subject to market conditions, with no guarantee of completion or specific terms. This follows their earlier filed shelf registration statement with the SEC. Morgan Stanley, SVB Securities, and Cowen are managing the offering.
Alpine Immune Sciences (NASDAQ: ALPN) reported significant clinical updates on its drug candidates ALPN-303 and Davoceticept (ALPN-202). ALPN-303 showed well-tolerated results in Phase 1 trials, targeting systemic lupus erythematosus (SLE) and other autoimmune diseases, with a Phase 2 study planned. Davoceticept demonstrated encouraging outcomes in renal cell carcinoma, particularly in combination with pembrolizumab. Management announced a webcast to discuss these developments, indicating a focused approach to advancing their clinical pipeline.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced that its management team will participate in investor conferences in September 2022. Key events include the H.C. Wainwright 24th Annual Global Investment Conference on September 12 at 7:00 a.m. PT, featuring a presentation by Chief Business Officer Remy Durand, and the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, focused on one-on-one meetings. A link to the H.C. Wainwright presentation will be available on the company's investor relations website.
FAQ
What is the current stock price of Alpine Immune Sciences (ALPN)?
What is the market cap of Alpine Immune Sciences (ALPN)?
What does Alpine Immune Sciences, Inc. specialize in?
What is povetacicept (ALPN-303)?
What are the core focus areas of Alpine Immune Sciences?
What recent achievement has Alpine Immune Sciences accomplished?
What is acazicolcept (ALPN-101)?
What collaborations has Alpine Immune Sciences engaged in?
What is the ticker symbol for Alpine Immune Sciences?
When was Alpine Immune Sciences founded?
What is the mission of Alpine Immune Sciences?
Where can more information about Alpine Immune Sciences be found?
